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Abstract 
 
The structural analysis of class B G protein-coupled receptors (GPCR), cell surface proteins responding to 
peptide hormones, has until recently been restricted to the extracellular domain (ECD). Corticotropin-releasing 
factor receptor type 1 (CRF1R) is a class B receptor mediating stress response and also considered a drug target 
for depression and anxiety. Here we report the crystal structure of the transmembrane domain of human CRF1R 
in complex with the small-molecule antagonist CP-376395 in a hexagonal setting with translational non-
crystallographic symmetry. Molecular dynamics and metadynamics simulations on this novel structure and the 
existing TMD structure for CRF1R provides insight as to how the small molecule ligand gains access to the 
induced-fit allosteric binding site with implications for the observed selectivity against CRF2R. Furthermore, 
molecular dynamics simulations performed using a full-length receptor model point to key interactions between 
the ECD and extracellular loop 3 of the TMD providing insight into the full inactive state of multidomain class 
B GPCRs. 
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Introduction  
The secretin subfamily of Class B G protein-coupled receptors (GPCRs) includes many important and clinically 
validated drug targets. These include the glucagon like peptide receptor GLP1 for diabetes, calcitonin gene 
related peptide receptor for migraine and the parathyroid hormone receptor PTH1 for osteoporosis [1]. 
Corticotropin releasing factor receptor (CRF1R) itself is an important drug target across a range of different 
disease areas outlined elsewhere in accompanying chapters.  In particular a focus of interest for many years by 
pharmaceutical companies is its role in stress related disorders such as depression [2].  Despite extensive efforts, 
Class B GPCRs have proved very intractable as drug targets and to date no small molecule modulators have 
reached the market. The CRF1 receptor is one of the few Class B receptors where small molecule antagonists, 
such as CP-376395 have been identified by high throughput screening [3].  In order to fully understand the 
precise mechanism of action of CP-376395 we set out to solve the X-ray structure of the CRF1R bound to CP-
376395.   
 
Major technological advances in the area of protein expression, purification and crystallization together with 
techniques to address the lack of stability and conformational flexibility of GPCRs have enabled the structures 
of over 20 Class A receptors to be solved. However, structures of Class B GPCRs have lagged behind. This is 
due in part to the lack of small molecule ligands for co-crystallization and the multi-domain architecture of class 
B GPCRs consisting of the membrane spanning 7-transmembrane domain and the extracellular peptide ligand 
binding domain. GPCR crystal structures are highly enabling for structure based drug design approaches [4] and 
also permitting homology models to be built for related receptors. However X-ray structures represent a ‘snap-
shot’ of one particular conformation of the protein/ligand complex providing limited information on the 
flexibility of the protein and no information relating to the dynamics of ligand binding. Molecular dynamic 
(MD) simulations are increasingly being applied to study GPCRs and are being actively used in drug design to 
provide information on the dynamics of conformational changes by the receptor as well as the complex interplay 
between the protein, water networks and ligand receptor interactions [5]. Here we have also used MD and 
metadynamics simulations to study ligand receptor interactions in CRF1R and the conformational changes which 
may occur in the full length receptor.  
 
 Materials and Methods 
Protein expression and purification 
The CRF1R-TMD carrying a T4 lysozyme fusion in intracellular loop 2 and a C-terminal deca-histidine tag was 
expressed in Trichoplusia ni (High Five) cells in EX-CELL 405 medium (Sigma-Aldrich) supplemented with 10 
% (v/v) fetal bovine serum (Sigma-Aldrich), 1 % (v/v) CD lipid concentrate (GIBCO) and 1 % (v/v) 
Penicillin/Streptomycin (PAA Laboratories). Cells were infected at a density of 2 x 10
6
 cells/ml with 10 ml of 
baculovirus per liter of culture, corresponding to an approximate multiplicity of infection (MOI) of 1. Cultures 
were grown at 27 °C with constant shaking and harvested 72 hours post infection. Cells were pelleted and 
washed with 250 ml PBS and stored at -80 °C. All subsequent purification steps were carried out at 4 °C unless 
indicated differently. To prepare membranes, cells were thawed at room temperature and resuspended in 400 ml 
ice-cold 50 mM Tris-HCl pH 8.0, 500 mM NaCl supplemented with EDTA-free protease inhibitors (Roche). 
The cell suspension was incubated with 0.3 µM CP376395 (Tocris) for 1 hour to allow the ligand to bind. Cells 
were disrupted by ultra-sonication and cell debris was removed by centrifugation at 10.000 x g. Membranes 
were collected by ultracentrifugation at 140.000 x g, resuspended and stored at -80 °C until further use. 
Membranes were thawed at room temperature and solubilized with 2 % (w/v) DM for 1.5 hours. Insoluble 
material was removed by ultra-centrifugation and the receptors were immobilized by batch binding to TALON 
metal-affinity resin (Clontech) for 2 hours. The resin was packed into a XK-16 column (GE Healthcare) and 
washed with steps of 8 and 30 mM imidazole in 50 mM Tris-HCl pH 8.0, 500 mM NaCl, 0.15 % (w/v) DM, and 
0.3 µM CP376395 for a total of 15-20 column volumes before bound material was eluted with 200 mM 
imidazole. The protein was then concentrated using an Amicon Ultra-15 centrifugal filter unit (Millipore) and 
subjected to preparative gel filtration in 20 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.15 % (w/v) DM, and 0.3 µM 
CP376395 on a Superdex 200 10/300 GL gel filtration column (GE Healthcare) to remove remaining 
contaminating proteins and aggregates. Receptor purity was analyzed using SDS-PAGE and mass spectrometry 
and receptor mono-dispersity was assayed by FSEC monitoring tryptophan fluorescence. Protein concentration 
was determined with a NanoDrop spectrophotometer using the receptor’s calculated extinction coefficient at 280 
nm (e280, calc = 1.6 (mg/ml x cm)
-1
). 
 
Crystallization 
The CRF1R-TMD was crystallized in lipidic cubic phase (LCP) at 22.5 °C. The protein was concentrated to 20-
30 mg/ml by ultrafiltration and mixed with monoolein (Nu-Check) supplemented with 10 % (w/w) cholesterol 
(Sigma) and 5 µM CP376395 using the twin-syringe method [6] with a final protein:lipid ratio of 1:1.5 (w/w). A 
Mosquito LCP (TTP Labtech) was used to dispense 40-60 nl boli on 96-well Laminex Glass Bases (Molecular 
Dimensions), overlaid with 0.75 µl precipitant solution and sealed with Laminex Film Covers (Molecular 
Dimensions). 20-30 µm crystals of construct CRF1R-#76 were obtained in 100 mM Na-citrate pH 5.5, 200 mM 
Li2SO4, 30 % (v/v) polyethylene glycol 400, 0.6 µM CP376395. Crystals were flash cooled in liquid nitrogen 
without additional cryoprotectant.  
 
Diffraction data collection and processing 
X-ray diffraction data were measured on a Pilatus 6M hybrid-pixel detector at Diamond Light Source beamline 
I24 using a 5 μm diameter microbeam. Crystals displayed isotropic diffraction to beyond 3.0 Å following 
exposure to an unattenuated beam for 8 seconds per degree of oscillation. Consequently radiation damage set in 
quickly and less than 5 degrees of oscillation data per crystal could be used in subsequent data merging. Data 
from individual crystals were integrated using XDS [7]. The final dataset included data from 21 crystals (with 
reindexing as required) and was scaled to 3.18 Å using the microdiffraction assembly method as described 
previously [8, 9] with a final overall completeness of 93.7 %. Crystals belonged to hexagonal space group P6 
with unit cell dimension of a = b = 189.4 Å, c = 88.6 Å, α = β = 90 ˚ γ = 120 ˚. The resulting multi-record 
reflection file was scaled using AIMLESS from the CCP4 suite [10, 11]. Data collection statistics are presented 
in Table 1.  
 
Structure solution and refinement 
The CRF1R-#76 crystals belong to hexagonal space group P6 exhibiting a 30 % off-origin peak in a native 
Patterson map, indicating translational non-crystallographic symmetry (tNCS). Previously, it was possible to 
modulate the construct in terms of the TMD and T4 Lysozyme (T4L) linker resulting in construct CRF1R-#105 
which crystallized in the same conditions as CRF1R-#76 yet belonged to an orthorhombic spacegroup displaying 
no tNCS and which was subsequently solved and refined (PDB ID: 4K5Y) [9]. The structure of CRF1R-#76 was 
solved by molecular replacement (MR) with the program Phaser [12] utilising corrections for the statistical 
effects of tNCS function [13] with two independent search models, T4L from CRF1R and the TMD of CRF1R 
(PDB ID 4K5Y). Solutions were found for all three copies of the T4L and TMD in the asymmetric unit. Manual 
model building was performed in COOT [14] using sigma-A weighted 2m|Fo|-|DFc|, m|Fo|-D|Fc| maps calculated 
using Phenix [15]. Initial refinement was carried out with REFMAC5 [11, 16] using maximum-likelihood 
restrained refinement in combination with the jelly-body protocol. Late stages of the refinement were performed 
with Phenix.refine [17] with positional and individual isotropic B-factor refinement and TLS. The structure was 
validated using MolProbity [18]. The final refinement statistics are presented in Table 1. Figures were prepared 
using PyMOL [19]. 
 
Structural analysis 
Cα RMSD calculation between different copies of the CRF1R-TMD structures was performed using Superpose 
[11]. The following amino-acid ranges were used 125-140(TM1), 154-164(TM2), 190-209(TM3), 241-
249(TM4), 272-291(TM5), 314-322(TM6) and 350-365(TM7). 
 
Molecular Dynamics Simulation 
The three dimensional coordinates of CRF1R (space group P22121, CRF1R
P22121
) in complex with the small 
molecule antagonist CP-376395 [9] were downloaded from the Protein Data Bank [20]. The receptor was 
prepared with the Protein Preparation Wizard in Maestro [21]: only the protein and the ligand in chain C have 
been included, hydrogen atoms have been added and the H-bond network has been optimized through an 
exhaustive sampling of hydroxyl and thiol moieties, tautomeric and ionic state of His and 180° rotations of the 
terminal dihedral angle of amide groups of Asp and Gln. His155
2.50
 has been considered to be protonated.  
Hydrogen atoms have been energy minimized using the OPLS2.1 force field. The same protocol has been 
applied to chain A of CRF1R in the hexagonal space group P6 (CRF1R
P6
), while for the MD simulation of the 
apo state of CRF1R
P22121
 the ligand CP-376395 has been deleted. The homology model of the receptor including 
the extracellular domain (ECD-CRF1R
P22121
) has been created using CRF1R
P22121
 chain A for the TMD and the 
crystal structure of the N-terminal extracellular domain available in the Protein Data Bank (PDB ID: 3EHS) 
[22]. The 6 residues missing between the two crystal structures (from E109 to V114) have been assumed to be 
helical creating one and half helical turn connecting the top of TM1 helix to the helix at the end of the ECD. The 
continuous helical nature of the link between the two domains determined their final relative orientation. The 
T4L has been removed, the ICL2 conformation has been predicted using Prime [23] and the final system has 
been prepared with the same protocol described above with the Protein Preparation Wizard in Maestro. 
 
The 4 prepared systems (CRF1R
P22121
, CRF1R
P6
, apo CRF1R
P22121
 and ECD-CRF1R
P22121
) have been analysed 
using standard MD simulations with the following protocol. The AMBER99SB force field (ff) [24] parameters 
were used for the protein and the GAFF ff [25] for the ligands using AM1-BCC partial charges [26]. The system 
has been embedded in a triclinic box including an equilibrated membrane consisting of 256 DMPC (1,2-
dimyristoyl-sn-glycero-3-phosphocholine) lipids [27] and 24513 waters using g_membed [28] in GROMACS 
(v4.6.5). The SPC water model was used and ions were added to neutralize the system (final concentration 0.01 
M). An energy minimization protocol based on 200 steps steepest-descent algorithm followed by 500 steps 
conjugate gradient algorithm has been applied to the system. The membrane has been equilibrated using 2 ns 
MD simulation with a time step of 2.5 fs, using LINCS on all bonds and keeping the protein and ligand 
restrained applying a force of 100 kJ
 
mol
-1 
nm
-1
. Lennard-Jones and Coulomb interactions were treated with a 
cut-off of 1.069 nm with particle-mesh Ewald electrostatics (PME) [29]. The MD has been executed in the NPT 
ensemble using v-rescale [30] (tau_t = 0.5 ps) for the temperature coupling to maintain the temperature of 303 K 
and using Parrinello-Rahman [31] (tau_p = 10.0 ps) for the semi-isotropic pressure coupling to maintain the 
pressure of 1.013 bar. Finally a 50 ns MD simulation has been performed using the same settings described 
above, but without applying any positional restraints. 
 
Metadynamics simulation  
Well-tempered Metadynamics (WTMetaD) [32] simulations have been used to evaluate: 1) the lowest energy 
binding path of CP-376395 to CRF1R
P22121
, 2) low energy conformations of the ECD relative to the receptor 
TMD. All simulations have been carried out using GROMACS with the same MD protocol described above and 
PLUMED (v2.0.2) [33] with a time step of 2 fs. 
 
Possible ligand binding and dissociation paths were initially generated using a steered MD [34] protocol. The 
method was based on 24 steps of 250 ps MD each for a total of 6 ns: 3 ns for the ligand binding and 3 ns for the 
dissociation event simulation, 12 steps each. Using a python script the protocol started with a target RMSD from 
the ligand bound conformation value of 10 Å and a force constant of 1 kJ mol
-1
 nm
-1
. To ensure the final ligand 
bound state was reached, the target RMSD value was consecutively decreased and kappa increased by 10-fold in 
the first 12 steps. For the dissociation 12 steered MD steps with the same settings were applied using as target 
position the initial unbound conformation of the ligand. Two possible binding-dissociation paths for the small 
molecule have been considered: one accessing the ligand binding site from the extracellular side and one from 
the membrane. These have been achieved positioning the ligand in different starting locations at about 20 Å 
from the bound state, respectively in the extracellular side close to the orthosteric site and into the membrane 
close to TM5. The obtained binding routes have been used to define a path collective variable (CV) for the 
WTMetaD with the following settings: simulated temperature 300 K, bias factor 90, initial energy bias Gaussian 
height of 0.3 kJ/mol with a deposition frequency of 500 MD steps. A geometric based hills width scheme [35] 
has been applied starting with a sigma value of 0.1. Two path collective variables have been defined [36] one 
defining the position on the path and the other the distance from the path. A Lambda value of 3.0 has been 
applied. A total of 58 ns WTMetaD starting from the ligand bound state were required to reach the lowest 
energy barrier allowing the ligand to dissociate from the receptor. 
 
A similar protocol has been used to identify stable “open” and “closed” conformations of the ECD relative to 
the receptor helical bundle. In this case the path CV has been defined using the starting and final protein 
conformations from the 50 ns MD of the ECD-CRF1R
P22121
. Two restraining potential walls have been applied 
to the CV describing the distance from the path at CV values of 0.3 and -0.3 (k=500 kJ mol
-1
 nm
-1
, exp=3). Two 
simulations for a total of 114 ns WTMetaD starting from the “open” and “closed” ECD states have been 
performed. This simulation length was not sufficient to obtain a converged energy landscape of the full 
conformational change for the full length receptor moving from the “open” to the “closed” ECD states. The 
protocol described identifies representative low energy ECD conformations of the two states. 
 
 
 
Results 
CRF1R Crystal Structures 
In 2013 the crystal structure of the TMD of CRF1R was reported at 3.0 Å resolution [9]. CRF1R was crystallised 
in Lipidic Cubic Phase (LCP) (Figure 1-D) using a conformational thermostabilisation approach to generate the 
stabilised receptor (StaR) and fusion of T4-Lysozyme (T4L) within intracellular loop 2 (ICL2) of the receptor to 
aid crystallisation (this construct is referred to as CRF1R-#105 henceforth). The full-length human CRF1R with 
an intact ICL2 (no T4L insertion) was used as background for generation of the StaR using a mutagenesis 
approach described previously and mutants analyzed for thermostability in the presence of the selective 
radioligand [
3
H]CP-376395. While wild type CRF1R displayed an apparent thermostability (Tm) of 18.4 °C 
(±2.0 °C) in n-dodecyl-β-D-maltopyranoside (DDM), the CRF1R StaR (full-length receptor with 12 
thermostabilizing mutations) displayed a Tm of 44.7 °C (±2.2 °C) in an identical assay, dropping to a Tm of 
37.5 °C (±0.7 °C) upon fusion of the T4L. The resulting structure of the human CRF1R receptor TMD in 
complex with the small molecule antagonist CP-376395 (2-aryloxy-4-alkylaminopyridine) in an orthorhombic 
setting (referred to as CRF1R
P22121
 henceforth) provided an exciting inaugural view of the architecture of the 
CRF1R receptor and that of class B GPCRs in general.   
 
However, these were not the first crystals of CRF1R to be obtained. In addition to CRF1R crystals grown using 
bicelles, and classical vapour diffusion (data not shown) the first generation of CRF1R TMD crystals grown 
(Figure 1-A) using the in meso method utilised a near identical construct to CRF1R-#105 but which incorporated 
two extra residues from intracellular loop 2 – one of which had been previously identified as a thermostabilising 
mutation (S222L) in the fusion to T4-Lysozyme (this construct is referred to as CRF1R-#76 henceforth). The 
CRF1R-#76 crystals belong to hexagonal space group P6 exhibiting a 30 % off-origin peak in a native Patterson 
map, indicating translational non-crystallographic symmetry (tNCS). Although a complete dataset to 3.18 Å 
resolution could be generated through merging data collected from multiple crystals, extensive trials to solve the 
structure by molecular replacement failed, due in part to the presence of tNCS and / or the low structural 
similarity between search model and target. With the CRF1R
P22121
 structure in hand it was finally possible to 
solve the hexagonal tNCS data (see methods) with three copies in the asymmetric unit, thereby generating a 
second structure of the CRF1R receptor in complex with CP-376395 referred to as CRF1R
P6
 henceforth (Table 1) 
and which doubles the structural information available for this receptor (Figure 1-B,C).  
The nature of the tNCS was unusual. The peak in the native Patterson map indicated a tNCS translation of 
approximately 1/3,2/3,0, from which one might expect three copies in the asymmetric unit to be generated by 
successive applications of the same translation vector, corresponding to an approximate tripling of a smaller unit 
cell. However, the tNCS likelihood target [13] was about 1600 units higher when assuming two tNCS-related 
copies instead of three. A molecular replacement search for two copies each of the TMD and T4L models gave 
an unambiguous solution, in which a crystallographic 3-fold axis generated hexamers from the two copies. The 
crystal packing left a hole around the crystallographic 6-fold axis, sufficient to place an additional copy 
generating a hexamer, but surprisingly the molecular replacement search for an additional copy each of the 
TMD and T4L placed them in an inverted orientation, so the third copy was not in fact related by translation to 
the first two. 
 
Despite fundamental differences in crystal contacts / packing between the orthorhombic and hexagonal lattices, 
superposition of the 6 CRF1R-TMD structures (3 copies in the asymmetric unit from both CRF1R
P22121
 and 
CRF1R
P6
) demonstrate the structures are all in close agreement (root-mean-square deviation RMSD less than 0.4 
Å across core TM residue Cα atoms – see methods) (Figure 1-G,H). In the hexagonal CRF1R
P6
 crystal system 
interactions between receptors occur exclusively via parallel packing with TM1 and TM7 from one receptor 
copy interacting with TM4 and the N-terminus of TM3 for both non-crystallographic and symmetry related 
copies (Figure 1-C). In the orthorhombic CRF1R
P22121
 crystal form interactions between receptors occur in both 
parallel and antiparallel fashion. Parallel interactions are observed between ECL3/TM6 to ECL3/TM6, TM1 to 
TM1, and TM1 to TM4/N-terminus of TM3, with a single antiparallel interaction from TM4 to TM4 (Figure 1-
F).  
 
The open extracellular conformation of the peptidic agonist orthosteric pocket initially revealed in the CRF1R
 
P22121
 structure is maintained across the 3 CRF1R
P6
 copies. One side of this “chalice-like” conformation is 
provided by TM2-TM5, and the other by TM1, TM6, and TM7. As previously reported, in CRF1R the slightly 
bent extracellular portion of TM1 packs against and stabilizes a kink in TM7 contributing to the open nature of 
the receptor extracellular vestibule. The highly conserved S130
1.50b
 on TM1 hydrogen bonds to the backbone 
Nitrogen of F357
7.51b
 and main-chain carbonyl of S353
7.47b
, which flank G356
7.50b
 on TM1. This results in the 
extracellular halves of TM6, TM7 and extracellular loop 3 (ECL3) tilting away from the central helical bundle 
[9]. Furthermore, the extracellular portions of TM6, TM7 and ECL3 (along with the N-terminus of TM1) 
demonstrate the highest B-factor values and structural variation across all 6 CRF1R-TMD structures, pointing to 
the inherent structural flexibility of this region in CRF1R (Figure 1-I,J). Indeed in only 2 of the 6 copies of the 
CRF1R receptor from both the CRF1R
P22121
 and CRF1R
P6
 is ECL3 ordered and visible in the electron density.  
 
Finally in all 3 copies of CRF1R
P6
 the CP-376395 small molecule is again visible in the extraordinary position 
towards the intracellular side of the receptor with a single hydrogen-bond supplied by N283
5.50b
, while TM3, 
TM5 and TM6 provide the residues that constitute the rest of the hydrophobic pocket towards the intracellular 
side of the receptor, as previously observed and in close agreement with the CRF1R
P22121
 structure (Figure 1-
G,H). 
 
Structural Insights into CP-376395 Binding and CRF1R Selectivity 
The striking position of CP-376395 and its interactions with the receptor resulted in a very stable configuration 
across a 50 ns Molecular dynamics (MD) simulation within an explicit water-membrane environment. For both 
crystal forms (CRF1R
P22121
 and CRF1R
P6
) the average ligand RMSD during simulation was ~1 Å. To evaluate 
whether the allosteric small-molecule binding site in CRF1R was induced by CP-376395 we also analyzed an 
apo CRF1R model using an identical MD simulation protocol. In this case the allosteric pocket appeared very 
unstable. TM6 quickly moved closer to TM3 in a position similar to that adopted in the glucagon receptor 
crystal structure (Figure 2-A). In particular residues M206
3.47b
 and L320
6.46b
 occupied and collapsed the binding 
site. These two residues have recently proposed to be part of the hydrophobic core of the receptor [1, 37] 
playing a crucial role in stabilizing the inactive receptor state by controlling the movement of the N-terminus of 
TM6 during activation, an essential structural prerequisite that is required for G protein docking on the 
intracellular surface of the receptor.  
 
To further investigate the nature of the induced-fit CP-376395 pocket within CRF1R, ligand binding and 
dissociation paths were generated using a Steered MD protocol. Two different starting positions of the small 
molecule were evaluated: one accessing the binding site from extracellular space; and one from within the 
membrane. Starting positions for CP-376395  were located ~20 Å from the crystallographic ligand bound 
position: in the first case this was on the extracellular side of the receptor close to the orthosteric site, while in 
the second it was within the membrane - in close proximity to TM5 (Figure 2-B). The Steered MD trajectories 
obtained were subsequently used for a well-tempered metadynamics (WTMetaD) simulation protocol starting 
from the bound crystallographic state. WTMetaD permitted the evaluation of the free energy surface of ligand 
dissociation (Figure 2-C). The most favourable and lowest energy escape route for the ligand from the induced-
fit pocket was between TM5 and TM6 and towards the membrane environment. Analysis of the simulation 
trajectory reveals crucial movements of F203
3.44b
 and Y327
6.53b
 changing rotameric states during ligand 
dissociation (Figure 3-A,B). These key conformational changes permit the initial movement of the ligand from 
the bound crystallographic state up and towards the extracellular side of the receptor creating a high-energy 
transition state conformation where the H-bond between CP-376395 and N283
5.50
 is broken. From this position 
the ligand can access the membrane between TM5 and TM6 in a location close to G324
6.50b
 and P321
6.47b
 
(Figure 3-C). Both G324
6.50b
 and P321
6.47b
 contribute to a bent / flexible local conformation of TM6 to create a 
sterically viable exit for CP-376395 from the receptor TMD. Finally, the movement of F203
3.44b
 and Y327
6.53b
 
during ligand dissociation (Figure 3-D) is influenced by M276
5.44b
 and H199
3.40b
. M276
5.44b
 and H199
3.40b
 have 
previously been demonstrated to be important for the observed selectivity of CP-376395 for CRF1R over 
CRF2R, where they are instead found to be Ile272
5.44b
 and Val195
3.40b
 respectively [38, 39]. 
 
Structural Insights into CRF1R Inter-Domain Interactions  
As expected, analysis of CRF1R
P22121
 and CRF1R
P6
 dynamic behaviour using MD simulation confirmed the 
conformations of both structures to be stable and in agreement.  Across a 50 ns MD simulation in an explicit 
water-membrane environment the average RMSD for all protein Cα atoms was measured at ~2 Å. Root mean 
square fluctuation analysis of the trajectories highlighted a high degree of flexibility for extracellular loop 3 
(ECL3) from residue N333 to E338 (Figure 4-A). This is in agreement with the high resultant B-factors and 
structural variation for residues in this region across both crystal forms and six receptor copies obtained for 
CRF1R-TMD (Figure 1-I,J). To investigate the observed flexibility of ECL3 and any potential structural role in 
the context of the full-length receptor, a full-length model using the CRF1R
P22121 
TMD and crystal structure of 
the extracellular domain (ECD) (PDB ID: 3EHS) [22] was built. The 6 residues (E109 to V114) connecting the 
ECD to the TMD of the receptor which are not resolved in any of the available crystal structures have been 
assumed to be alpha helical and therefore modelled as one and half helical turns connecting the C-terminus of 
the ECD with the N-terminus / top of TM1. The assumption of continuous alpha helix in ab initio modelling of 
these 6 residues, connecting experimentally resolved regions of alpha helix which flank either side, determined 
the relative orientation of the two protein domains in the final full-length CRF1R model. 
 
The conformational stability between the CRF1R –TMD and ECD was initially analyzed using a standard MD 
simulation within an explicit water-membrane environment. In the starting conformation the main interactions 
between the two domains are between ECL3 of the receptor TMD and Loop 2 of the ECD. During the 50 ns MD 
simulation the ECD changed its relative position to adopt a final “closed” conformation on top of the receptor 
TMD. In the final state model Loop 1, Loop 2 and the C-terminus of the ECD adopt a position closer to ECL1 
and ECL2 of the TMD. After structural superimposition of the starting and final state full-length models using 
the TMD regions only, the Cα RMSD for the ECDs was ~18 Å, with a maximum change for Loop 3 in the ECD 
greater than 45 Å. In order to identify the most stable “open” and “closed” conformations of the ECD in the full 
length receptor the system was analyzed using a WTMetaD protocol.  
 
The analysis highlighted the potential integral role of charged residues and electrostatic interactions in 
mediating interactions in the juxtamembranous (JM) region connecting TM1 to the ECD, and between ECL3 of 
the TMD to the ECD to control the relative position of the two CRF1R domains. In the “open” conformation 
D337 and E338 within ECL3 form salt bridges with ECL2 (R263) and the ECD (R76) respectively. In the 
“closed” conformation, R3417.35b (in close proximity to ECL3) interacts with E108 in the JM region (Figure 4-
C) and together with the adjacent E109, K110, K111 and K113 appears to play a key role in stabilizing the full-
length receptor “closed” state. Furthermore the JM region can partially unwind allowing D337 in ECL3 to 
interact with R76 and K113 further locking the ECD and thus full-length CRF1R in the “closed” conformation 
(Figure 4-D). 
 
 
 
Discussion 
The crystal structure of the CRF1R TMD in a hexagonal setting represents a doubling of the structural 
information that exists for this receptor in the public domain. That the CRF1R
P6
 and CRF1R
P22121
 structures are 
in close agreement in terms of structural superposition of the TMD regions, with molecular features maintained 
across crystal systems / fundamentally different lattices (and exhibit a comparable and extremely stable 
dynamics behaviour) further increases confidence that the molecular features of the ground state of the receptor 
TMD are captured across these structures. Additionally the structure of the human class B glucagon receptor 
TMD was reported at 3.4 Å resolution in 2013 in complex with the antagonist NNC0640 [40]. Though the 
position of NNC0640 was not determined in the glucagon crystal structure, superposition of the TMD of CRF1R 
and glucagon receptors demonstrates considerable structural conservation of the canonical 7TM helix 
arrangement (particularly over TMs 1-5) [1]. Taken together this represents a reliable structural framework from 
which to investigate the complexity of the inactive CRF1R conformation, and potentially multidomain class B 
receptors in general. Additionally we can gain insight into the nature of the CRF1R small-molecule allosteric 
binding site, the protein conformational changes required for the ligand binding event and implications for 
selectivity. Finally a molecular model of full-length CRF1R in the inactive state has been assembled and 
optimized using unbiased and biased MD. 
 
MD simulation using an apo CRF1R model strongly suggests that the allosteric pocket found deep towards the 
intracellular side of the receptor is induced by ligand binding (Figure 2-A). Steered MD supports two possible 
access routes for the ligand to the induced-fit site in CRF1R: one from the putative orthosteric site in the 
extracellular side of the receptor and a second from within the membrane, in a location close to TM5 and TM6 
(Figure 2-B). WTMetaD analysis of the free energy surface of the ligand dissociation suggests that the lowest 
energy escape route for the ligand from the induced-fit pocket is between TM5 and TM6 toward the membrane 
(Figure 2-C). During ligand dissociation F203
3.44b
 and Y327
6.53b
 change rotameric states (Figure 3-D) permitting 
exit of the small-molecule from the CRF1R-TMD in a region close to G324
6.50b
 and P321
6.47b
 (Figure 3-C). 
These predicted conformational changes required for ligand binding and dissociation also provide a potential 
rationale for the selectivity of CP-376395 to the human CRF1R subtype. The functional antagonist activity of 
CP-376395 for CRF1R is 12 nM, while >10000 nM for CRF2R [3]. Sequence identity within the helical bundle 
between the receptor subtypes is high (78%) and residues participating in direct interactions with CP-376395 in 
CRF1R are completely conserved in CRF2R. Across the second shell of residues in proximity of CP-376395 
(less than 5 Å) only two residues differ between CRF1R and CRF2R, these being H199
3.40b
 and M276
5.43b
 
corresponding to V195
3.40b
 and I272
5.43b
 respectively. Mutation of these residues in CRF1R to the corresponding 
amino acids in CRF2R has been demonstrated to reduce the binding affinity of standard non-peptide antagonists 
in CRF1R while concomitantly having little effect on peptide ligand binding [38, 39]. From the WTMetaD 
simulation M276
5.44b
 and H199
3.40b
 appear to play a crucial role in modulating the conformational changes of 
F203
3.44b
 and Y327
6.53b
 required for CP-376395 binding / dissociation. In CRF2R the corresponding V195
3.40b
 
and I272
5.43b
 may potentially lock F
3.44b
 and Y
6.53b
 in a conformation incompatible with CP-376395 gaining 
access to the induced-fit allosteric site. 
 
The ECD of CRF1R has been shown previously to act as an intrinsic negative regulator of receptor activity, with 
ECL3 of the TMD playing an important role in mediating crosstalk with the ECD [41, 42]. Using a full-length 
CRF1R model and WTMetaD protocol, representative low energy conformations of the ECD in “open” and 
“closed” states relative to the TMD have been identified. Mutagenesis, photoaffinity labelling and cysteine 
trapping studies all provide experimental evidence that in addition to roles played by the extracellular loops, the 
JM region (connecting TM1 to the ECD) plays an important role in the structure, function and context of full-
length multidomain class B receptors [43]. The results presented here implicate electrostatic interactions 
between ECL3, the ECD, and the JM region as the major determinants in the relative positioning of the two 
receptor domains. In particular ECL3 appears to play a critical role in mediating interactions between the TMD 
and the ECD, maintaining the CRF1R ECD in an inactive “closed” conformation with the receptor TMD, as 
recently proposed for the glucagon receptor [41]. Studies of the multidomain calcitonin gene related peptide 
receptor have also previously identified point mutations in ECL3 that result in a significant increase of both 
basal and ligand-induced activity for this receptor [44]. The result of the WTMetaD highlights the role of E338 
from ECL3 in forming a salt bridge with R76 from the ECD, indeed mutagenesis of R76 in CRF1R to the 
corresponding residue in either human vasoactive intestinal peptide receptor type 2 (hVIP-R2) or CRF1R from 
Xenopus laevis abolishes CRF1R peptide ligand binding [45]. Finally E336 in ECL3 is predicted to interact with 
Y73 from loop 2 on the CRF1R ECD in the “closed” state and mutation of the corresponding residue to alanine 
in the ECD of the glucagon receptor (Y65A) increases basal activity almost fivefold [41]. Taken together this 
provides experimental evidence corroborating the modelled interactions in CRF1R that are important for 
positioning the ECD relative to the TMD in a functional context. In terms of activation it is possible that 
following initial binding of the 41 amino acid corticotropin-releasing hormone to the ECD [46, 47], the peptide 
agonist then relieves receptor inactivation through affecting ECD interactions with ECL3 before subsequently 
binding to the TMD to induce receptor activation.  
 
Conclusions 
 
The structure of CRF1R in complex with the small molecule CP-376395 at 3.0 Å [9] and in a hexagonal setting 
at 3.2 Å as presented here have greatly increased our understanding of the architecture of class B receptors 
including the configuration of the TMD, the open chalice-like nature of the extracellular vestibule and peptidic 
orthosteric peptide binding pocket and finally the location of a small-molecule induced-fit allosteric pocket deep 
within the TMD towards the intracellular side of the receptor. The molecular model of full length CRF1R 
corroborates the role of the ECD as an intrinsic negative regulator of the receptor activity. To further our 
understanding of the mode of action of CRF1R, and Class B GPCRs in general, structures of the full-length 
receptor are now required and will represent a significant advance for the field, either in the antagonist close 
conformation, or in the full agonist state with the corticotropin-releasing hormone (CRH) peptide or a peptide 
mimetic bound.  
 
Co-ordinates and structure factors have been deposited in the Protein Data Bank under the accession code 4Z9G 
 
 
 
Conflict of Interest. The authors from Heptares Therapeutics declare competing financial interests. 
 
 
 
Acknowledgments We thank G. Evans, R. Owen and D. Axford at I24, Diamond Light Source, Oxford, UK for 
technical support. We thank A. W. Leslie and R. Henderson at the MRC - Laboratory of Molecular Biology, 
Cambridge, UK. We also thank R. Nonoo and other colleagues at Heptares Therapeutics Ltd. for suggestions 
and comments. R.J.R is supported by a Principal Research Fellowship from the Wellcome Trust (grant No. 
082961/Z/07/Z). 
 
Author Contributions A.S.D. designed crystallization constructs, established the platform/protocols for, and 
carried out LCP crystallization and designed crystal optimization, harvested crystals, collected and processed X-
ray diffraction data and refined the structure. R.K.Y.C. performed expression / purification and grew crystals in 
bicelles, vapour diffusion and collected X-ray diffraction data. K.H. designed and characterized truncation / 
fusion and crystallisation constructs, established procedures for, and carried out expression and purification, 
established the platform/protocols for and carried out lipidic cubic phase (LCP) crystallization, collected and 
processed X-ray diffraction data. R.J.R. solved the novel CRF1R structure. Computational analysis of the 
structure and modeling was carried out by A.B. The manuscript was prepared by A.S.D., A.B. and F.H.M. 
Figure Legends 
 
Figure 1. Overview of the CRF1R crystal structures solved in complex with CP-376395. A - Left) Crystals 
grown in lipidic cubic phase of CRF1R-#76 – hexagonal setting. B) The overall structure of CRF1R-#76 solved 
with three copies in the asymmetric unit. CRF1R-T4L fusion is shown in ribbon representation and coloured by 
chain, pink, blue and green. The CP-376395 small-molecule is depicted in space fill representation with carbon, 
nitrogen and oxygen atoms coloured yellow, blue and red respectively. CRF1R-TMD and T4L fusions are 
denoted. C) Crystal packing of CRF1R in the hexagonal setting – view down unique c axis. Receptor copies 
coloured as in (B). D - Right) Crystals grown in lipidic cubic phase of CRF1R-#105 – orthorhombic setting. E) 
The overall structure of CRF1R-#105 solved with three copies in the asymmetric unit. CRF1R-T4L fusion is 
shown in ribbon representation and coloured by chain, pink, blue and green. The CP-376395 small-molecule is 
depicted in space fill representation coloured as in (B), CRF1R-TMD and T4L fusions are denoted. F) Crystal 
packing of CRF1R in the orthorhombic setting – view down a axis. Receptor copies coloured as in (B). G - 
Centre) Superposition of all 6 CRF1R-TMD copies in ribbon representation coloured in varying shades of cyan 
as viewed from a plane parallel to the membrane. TM helices are labeled. CP-376395 is labeled and shown in 
stick representation coloured as in B. H) Close-up view of the induced-fit small-molecule allosteric site in 
CRF1R – receptor copies coloured as in (G). Important receptor residues are labeled and shown in stick 
representation with carbon, nitrogen and oxygen atoms coloured white, blue and red respectively. CP-376395 is 
labeled and shown in stick representation coloured as in B. Hydrogen bonds depicted as dashed red lines. I) 
Superposition of all 6 CRF1R-TMD copies as in (G) shown in sausage representation coloured using a relative 
B-factor spectrum, blue=low; red=high. J) Representation as in (I) rotated to view from extracellular space. 
 
Figure 2.  Analysis of CP-376395 binding to CRF1R. A) Comparison of CP-376395-CRF1R
P22121
 complex (in 
magenta), apo CRF1R
P22121
 (in green) and GCGR crystal structure (in cyan). Residues M206
3.47
 and L320
6.46
 are 
shown in space fill representation with carbon, nitrogen and oxygen atoms coloured green, blue and red 
respectively. CP-376395 is shown in stick representation with carbon, nitrogen and oxygen atoms coloured 
magenta, blue and red respectively B) The two predicted ligand binding paths are compared, in pink starting 
from the orthosteric site and in yellow from within the membrane. Binding paths are shown using snapshots of 
the ligand position during the simulation of binding and dissociation. The protein backbone is shown in cyan as 
ribbon. C) Free energy landscape predicted by the WTMetaD simulation for the dissociation event of CP-
376395. Y axis represents the path CV defining the position on the path, while the X axis the distance from the 
path CV. The free energy surface is colour-coded from yellow to red (0 to -137 kJ/mol) and the positions of the 
bound and dissociated states are indicated. 
 
Figure 3. Key conformations identified during the WTMetaD ligand dissociation path. The ligand and 
relevant receptor residues are shown in stick representation. N283
5.50
 provides the only H-bond with the CP-
376395 ligand while G324
6.50
 and P321
6.47
 modulate the bent trajectory of TM6. F203
3.44
 and Y327
6.53
 change 
rotameric states during ligand dissociation and are controlled by M276
5.44
 and H199
3.40
. In CRF2R these two 
residues are an I272
5.44
 and V195
3.40
 respectively. A) CP-376395 in the bound crystallographic conformation. B) 
Predicted first step in CP-376395 dissociation associated with breaking the H-bond with N283
5.50 
and changes in 
the conformation of F203
3.44
 and Y327
6.53
 to permit initial movement of the ligand toward the extracellular side 
of the receptor. C) The CP-376395 exit route between TM5 and TM6 close to G324
6.50
 and P321
6.47
. D) 
Comparison of the three ligand dissociation states (starting in magenta, first step in yellow and final step in 
green). The movement of F203
3.44
 and Y327
6.53
 are depicted in line representation. 
 
Figure 4.  Analysis of the extracellular surface of CRF1R. A) Side view of the extracellular region of the 
CRF1R receptor TMD highlighting the flexibility of ECL3 during MD simulation. Residues predicted to be 
crucial in determining the loop flexibility are shown in stick representation. B) On the left, superimposition of 
different snapshots from MD simulation of ECD-CRF1R
P22121
. On the right, comparison between the starting (in 
magenta) and final (in green) conformations of the receptor ECD. Representative lowest energy conformations 
identified by the WTMetaD protocol for the full length receptor with the ECD in the “open” (C) and “closed” 
(D) conformations are shown. Relevant residues are represented as sticks and the backbone as cartoon. The 
protein is colour coded as rainbow, from blue (N terminus) to red (C terminus). Key interactions are shown as 
yellow dotted lines. 
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Table 1. Crystallographic table of statistics. 
DATA COLLECTION  
Space Group P6 
Cell Dimensions  a, b, c, ( Å ) 189.4, 189.4, 88.6 
Cell Angles α, β, γ ( ° ) 90, 90, 120 
Resolution ( Å ) 3.18 
Rmerge 0.158 (0.627) 
I / σ I * 6.4 (1.8) 
Completeness ( % ) 93.7 (82.0) 
Redundancy 3.8 (2.5) 
REFINEMENT  
Resolution ( Å ) 19.91 – 3.18 
No. Reflections 28,393 
Rwork / Rfree 24.4 / 28.9 
No. atoms 
                   Protein 
                   Ligand 
 
9,980 
264 
B-factors 
                   Protein 
                   Ligand 
 
90.7 
85.5 
R.m.s deviations 
                   Bond lengths ( Å ) 
                   Bond Angles ( ° ) 
 
0.006 
0.882 
Ramachandran Plot: Preferred (%) 
                                 Allowed (%) 
                                 Outlier (%) 
96.4 
3.4 
0.2 
*Statistics in parentheses refer to outer resolution shell. 
 
